Protocol Ledger

NCT07235293 · Phase II · RECRUITING

A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

Interventional Phase II clinical trial protocol NCT07235293 sponsored by Kahr Bio Australia Pty in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-01-16 Enrollment: 90 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07235293
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)90 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07235293
Protocol FieldVerified Registry Value
NCT IdentifierNCT07235293
Consolidated Lead SponsorKahr Bio Australia Pty
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment90 participants (ESTIMATED)
Registered Start Date2026-01-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07235293
Hospital Research SiteLocationSite Profile
University of Colorado Anschutz Medical CampusAurora, COOpen Hospital Dossier ->
Duke University Medical CenterDurham, NCOpen Hospital Dossier ->
UPMC Hillman Cancer CenterPittsburgh, PAOpen Hospital Dossier ->
Chris O'Brien LifehouseCamperdown, AustraliaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI